Clinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.

Case Reports in Infectious Diseases is a premier open-access journal published by Hindawi Ltd, dedicated to advancing the field of infectious disease research through the dissemination of case reports that highlight unique clinical presentations, innovative treatment approaches, and novel diagnostic techniques. Since its inception in 2011, this journal has provided a vital platform for healthcare professionals, academicians, and researchers to share their findings, thereby enhancing the collective understanding of infectious diseases. Featuring a diverse range of case studies, the journal aims to inspire further research and clinical inquiry, making it an invaluable resource for anyone involved in the fight against infectious diseases. With an easily accessible online format, it caters to a global audience, ensuring that critical insights are available to all stakeholders in this crucial field.

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, published by Elsevier, is a prestigious academic journal that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, biophysics, and proteomics. With an ISSN of 1570-9639 and an E-ISSN of 1878-1454, this journal features high-impact research articles aimed at advancing our understanding of protein structure, function, and interactions, contributing significantly to both theoretical and applied sciences. Recognized for its quality, it proudly holds a Q1 ranking in Analytical Chemistry and Biophysics, and Q2 in Biochemistry for 2023, alongside notable Scopus rankings that reflect its influence in the realm of molecular biology. The journal's commitment to disseminating essential findings supports the ongoing evolution of proteomic sciences and encourages collaborative discourse among the global scientific community. For aspiring authors, the journal offers open access options, enabling broad visibility of their work. Join the conversation in this dynamic field and contribute to shaping the future of protein research!

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.

PROTEIN AND PEPTIDE LETTERS is a prominent peer-reviewed journal published by Bentham Science Publishers Ltd, specializing in the dynamic fields of biochemistry and structural biology. With an ISSN of 0929-8665 and a corresponding E-ISSN of 1875-5305, the journal has been a pivotal platform for researchers since its inception in 1994. Spanning various aspects of protein and peptide research, it aims to disseminate groundbreaking findings that enhance our understanding of molecular mechanisms and therapeutic applications. Although categorized in the Q3 quartile for biochemistry and medicine, and Q4 in structural biology within the 2023 metrics, it remains a valuable resource in the academic arena, offering insight into the latest research and advancements. As the journal converges towards its 2024 milestone, it continues to reflect the evolving landscape of molecular research. While it currently does not offer open access, the accessibility to its impactful content is essential for students, professionals, and researchers invested in these critical scientific disciplines.

Journal of the Pediatric Infectious Diseases Society, published by Oxford University Press, stands as a pivotal platform for advancing knowledge in the realm of pediatric infectious diseases. With an ISSN of 2048-7193 and an E-ISSN of 2048-7207, this esteemed journal has garnered significant recognition in the academic community, achieving influential rankings such as Q1 in Pediatrics, Perinatology and Child Health and Q2 in Infectious Diseases. With converged years from 2012 to 2024, it aims to publish cutting-edge research, reviews, and clinical practices that address the challenges and innovations in the field. The journal's strong performance, reflected in its Scopus ranks (33rd percentile in Pediatrics and 97th in Infectious Diseases), underscores its impact on the global healthcare landscape. As a non-open access journal, it provides exclusive content essential for researchers, medical professionals, and students dedicated to enhancing pediatric healthcare outcomes.

Case Reports in Pediatrics is a distinguished journal dedicated to the publication of high-quality case reports that illuminate specific pediatric clinical challenges and advancements. Published by HINDAWI LTD, this journal has established itself as an essential resource in the field of pediatric medicine, offering an open-access platform since 2011 to ensure that researchers, healthcare professionals, and students have unrestricted access to valuable insights. With an ISSN of 2090-6803 and an E-ISSN of 2090-6811, the journal aims to foster knowledge exchange and further the understanding of pediatric healthcare practices. This publication not only encourages the sharing of unique and rare case studies but also promotes best practices and innovative methodologies. In a rapidly evolving field, Case Reports in Pediatrics serves as a vital tool for professionals seeking to enhance patient care and inform clinical decision-making.

JOURNAL OF PROTEOME RESEARCH is a premier publication in the field of proteomics, disseminating cutting-edge research and methodologies that drive advancements in biochemistry and molecular biology. Published by the American Chemical Society, this esteemed journal boasts a robust impact, as evidenced by its Q1 rankings in both Biochemistry and miscellaneous Chemistry categories for 2023. With a reputation bolstered by a solid Scopus ranking—#64 out of 408 in General Chemistry and #80 out of 438 in Biochemistry—the journal serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of protein functions and interactions in biological systems. Although it does not operate under an open-access model, the JOURNAL OF PROTEOME RESEARCH remains a critical platform for scholarly discourse, committed to publishing high-quality, peer-reviewed articles through 2024 and beyond. Scholars are encouraged to engage with the pioneering studies and reviews that shape the future of proteomics.